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Abstract
Introduction: Accelerated liver function deterioration has been recognized in renal transplant recipients infected
with hepatitis C virus (HCV). Although combination therapy with interferon plus ribavirin has been established as
the standard treatment for patients with chronic HCV, the high risk of allograft rejection associated with interferon
therapy has greatly discouraged the clinical use of this regimen. In Asia, where chronic hepatitis B virus (HBV) is
prevalent, dual infection with HBV and HCV poses an even greater challenge for clinical hepatologists.
Case presentation: In this article, we report the case of a 51-year-old Taiwanese man with dual infection with HBV
and HCV prior to renal transplantation. Low-dose interferon (3 to 6 × 106 U/week) and ribavirin (100 mg/day to
200 mg/day) were prescribed following the reactivation of the man’s HCV after renal transplantation. Additionally,
lamivudine (100 mg/day) was administered concomitantly to prevent HBV reactivation. His initial serum HCV RNA
concentration was 5.2 × 106 copies/mL (genotype 2a). After three and one-half years of antiviral therapy, his HCV
was successfully eradicated without any episodes of allograft rejection. His serum HCV RNA remained negative six
months after withdrawal from interferon and ribavirin treatment. His serum HBV DNA remained undetectable
throughout the course of therapy.
Conclusion: Low-dose, long-term interferon therapy may achieve sustained eradication of HCV in the renal
transplant recipient with dual infection with HBV and HCV.
Introduction
Chronic hepatitis C virus (HCV) infection may lead to
severe sequels such as liver cirrhosis and hepatoma [1].
It was recognized as an important cause of morbidity
and mortality in renal transplant recipients [2]. Besides
accelerated deterioration of liver function in chronic
HCV infection, HCV-related glomerulopathy [3] and
HCV-associated fibrosing cholestatic hepatitis [4] have
also been documented in renal transplant recipients.
Although interferon plus ribavirin combination therapy
has been established as the standard treatment for
chronic HCV infection, the risk of acute rejection asso-
ciated with interferon administration has greatly hin-
dered the use of this treatment [5]. In an area where
chronic hepatitis B virus (HBV) infection is prevalent,
such as Asia, the challenge is even greater, because dual
infection with HBV and HCV may be encountered.
Mutual interference of HCV and HBV replication has
been reported in many studies with alternately dominant
hepatitis activities caused by HBV and HCV [6]. More
severe liver diseases have been observed in patients with
dual HBV and HCV infections. The strategy for treating
a renal transplant recipient carrying both HBV and
HCV with deteriorating hepatic function remains unde-
termined. In this article, we report the case of a renal
transplant recipient who had dual infection with HBV
and HCV prior to undergoing transplantation. Low-dose
interferon and ribavirin were prescribed following the
* Correspondence: chauting@adm.cgmh.org.tw
3Liver Cancer Research Center, Chang Gung Memorial Hospital, 6J
Laboratory, Linko Medical Center, 199 Tung Hwa North Road, Taipei, Taiwan;
Graduate Institute of Clinical Medical Sciences, Chang Gung University,
College of Medicine, Taoyuan, Taiwan
Full list of author information is available at the end of the article
Chang et al. Journal of Medical Case Reports 2011, 5:246
http://www.jmedicalcasereports.com/content/5/1/246 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Chang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
reactivation of HCV infection in this patient due to the
use of immunosuppressants. The patient’s serum HCV
RNA was successfully eradicated after three and one-
half years of antiviral therapy without any episodes of
allograft rejection.
Case presentation
A 51-year-old Taiwanese man had received regular
hemodialysis three times weekly for six years when he
was diagnosed with end-stage renal disease. Chronic
HBV and HCV infection had been diagnosed at the
beginning of hemodialysis on the basis of serological
tests. His HBV surface antigen (HBsAg) test had been
positive since his first hospital visit, and his antibody
against HCV was positive three years after the initiation
of hemodialysis. His HBV DNA was assayed twice seven
years later. The results of his HCV-RNA and HBV-DNA
quantitative tests were 5.9 × 105 copies/mL and 4.1 ×
106 copies/mL, respectively. Cadaveric renal transplanta-
tion was performed six years after his hemodialysis
treatment was initiated. Immunosuppressants had been
administered since that time, including prednisolone,
mycophenolate mofetil, cyclosporine and tacrolimus.
Over the next two years, he was admitted to our hospi-
tal 14 times for various reasons, including pulmonary
cytomegalovirus infection, urinary fungal infection, lip
herpes viral infection, acute allograft rejection, pulmon-
ary tuberculosis, tuberculous cystitis, hyperuricemia and
ureter stricture with obstructive nephropathy. One year
after he underwent renal transplantation, antituberculo-
sis therapy was administered for one year with treat-
ment regimens of isoniazid, rifampin, and ethambutol
for three months, followed by isoniazid alone for seven
months.
His liver biochemistry tests (aspartate aminotransfer-
ase, alanine aminotransferase (ALT) and bilirubin) were
normal until three years after renal transplantation,
when mild elevated aminotransferase levels about one to
threefold the upper limit of normal were noted. Predni-
solone was withdrawn at the same time. Marked eleva-
tion of aminotransferase levels (up to sevenfold the
upper limit of normal) associated with jaundice (biliru-
bin 3 mg/dL to 4 mg/dL) were found one year after the
administration of prednisolone. His HBV DNA was
below the detection limit (<300 copies/mL), whereas his
HCV RNA was 5.2 × 106 copies/mL. A HCV genotype
assay indicated genotype 2a. One year later lamivudine
therapy (100 mg/day) was prescribed and was continued
for the next two years. Upon the acute exacerbation of
liver function, ribavirin monotherapy was given inter-
mittently at 200 mg/day for nine months and 200 mg
every other day for the following two months. A liver
biopsy was taken one year later, which revealed chronic
active hepatitis with a Knodell Histology Activity Index
score of 10 (periportal necrosis, 3; intralobular necrosis,
1; portal inflammation, 3; and fibrosis, 3) as well as
marked fatty change. The patient’s immunohistochemis-
try study for HBsAg was positive. Combination therapy
of ribavirin (200 mg/day or every other day) and inter-
feron a-2b (3 × 106 U by subcutaneous injection once
to twice weekly) was started one year after his acute
exacerbation of liver function. The doses were adjusted
according to the tolerability of the host as well as the
blood tests (Figure 1). His combination therapy was
ended in four years. His ALT levels fluctuated between
100 U/L and 260 U/L (up to sevenfold the upper limit
of normal) during the first two years of his acute liver
exacerbation, which decreased gradually thereafter. Ulti-
mately, his ALT levels remained between one- and two-
fold the upper limit of normal. Sequential follow-up
with liver sonography showed mild parenchymal liver
fibrosis with moderate change in fatty liver. Negative
results of his serum HCV RNA were documented once
one year before the end of combination therapy and
three times at the end of the combination therapy. His
HBV DNA was below the detection limit after the with-
drawal of prednisolone therapy (a total of six times over
the next six years).
Discussion
Coinfection of HBV and HCV is a complicated issue
commonly encountered in an area where HBV is preva-
lent, such as Asia. Dual HBV and HCV infections have
been found to accelerate the clinical deterioration of
patients with liver disease compared with patients with
a single hepatitis virus infection [6]. In patients under-
going organ transplantation, liver diseases are even more
difficult to control, owing to the need for extensive
immune suppression. In patients undergoing liver trans-
plantation, long-term lamivudine therapy has been
recommended for HBV carriers to prevent reactivation of
the disease [7]. However, in renal transplant recipients,
the beneficial effect is not well-established. Mutual inter-
ference of viral replication between HBV and HCV has
been described in several reports [5,6]. In our patient,
HBV DNA was initially detectable (5.9 × 105 copies/mL
to 4.1 × 106 copies/mL), but became negative during
flares of HCV. It is possible that after HCV was sup-
pressed by antiviral therapy, HBV could have been reacti-
vated. Lamivudine was thus given concomitantly for this
patient. In our hospital, lamivudine was not available
until 1999, and, under the National Health Insurance Pol-
icy in Taiwan, the duration of lamivudine use was limited
to one and one-half years for each patient.
Although combination therapy with interferon plus
ribavirin has been established as the standard treatment
for chronic HCV infection, the strategy for posttransplan-
tation anti-HCV therapy remains inconclusive [2]. In our
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patient, a liver biopsy prior to anti-HCV therapy revealed
obvious fibrosis and necroinflammation. If these condi-
tions had been left untreated, the chance that this patient
would develop liver cirrhosis was great. They are also the
main cause of hepatocellular carcinoma [8]. The HCV
RNA genotype in this patient was 2a, a favorable factor
for anti-HCV therapy [9,10]. Attempts have been made
to treat HCV infection in renal transplant recipients
using various regimens, including ribavirin alone, combi-
nation therapy with ribavirin and amantadine [10], inter-
feron in combination with ribavirin [5,11] and interferon
alone [12]. Combination therapy of ribavirin with aman-
tadine was found not to be superior to ribavirin mono-
therapy, which resulted in a good biochemical response
but was not associated with virological clearance [5].
Intravenous interferon-b therapy given daily for six weeks
was reported to induce seroclearance of HCV in a renal
transplant recipient with stable renal function [12]. Low-
dose interferon-a in combination with ribavirin was
effective in some patients after a minimum therapeutic
period of six months, although it was poorly tolerated
and resulted in graft dysfunction in a significant number
of patients [5]. Ultra-low-dose interferon-a (1 × 106 U
given subcutaneously three times weekly) plus ribavirin
(600 mg/day) for 48 weeks was reported to clear HCV
RNA in five of 11 renal transplant recipients, but acute
graft failure (in one patient) and sepsis (in two patients)
also occurred [11]. Taken together, interferon and riba-
virin could eradicate HCV infection in selected renal
transplant recipients, but the dose needs to be adjusted
as needed to avoid allograft rejection. On the other hand,
recent studies have indicated that patients with chronic
HCV who fail to achieve viral clearance could benefit
from long-term low-dose interferon maintenance therapy
and that the histological deterioration in these patients
could be prevented [13,14]. In the present case, the
course of HCV therapy lasted for three and one-half
years, which is much longer than any other case reported
in the literature. Neither allograft rejection nor significant
infection was noted. Intriguingly, HCV infection was suc-
cessfully eradicated at the end of therapy and no relapse
has occurred to date. Interferon-a rather than pegylated
interferon was chosen as the therapy for this patient
because the longer half-life of the latter regimen might
be associated with a higher chance of allograft rejection.
After the end of treatment, the patient’s ALT levels were
still mildly elevated. Since both his HBV DNA and HCV
RNA were negative, it was likely that fatty liver rather
than viral hepatitis accounted for his elevated amino-
transferase levels.
Conclusions
Low-dose long-term interferon therapy could achieve
sustained eradication of HCV infection in renal trans-
plant recipients with dual HBV and HCV infections.
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